etranacogene dezaparvovec基因治疗B型血友病2b期试验5年完成结果
这项2b期、开放标签、单剂量、单臂、多中心试验纳入3例重型或中重型B型血友病(FIX≤2%)且AAV5中和抗体阳性的成年受试者,单次静脉输注etranacogene dezaparvovec(2×10^13基因组拷贝/kg)。5年随访显示FIX活性维持、出血率低、无FIX预防治疗,安全性和耐受性良好。
要点
- 第5年FIX活性均值45.7 IU/dL(范围39.0-51.2),0至5年累积随访年均出血率0.14。
- 全部受试者停用FIX预防治疗并保持无预防治疗,2例受试者治疗后5年无出血。
- 5年内无临床显著肝酶升高、无需激素、无FIX抑制物、无血栓并发症及迟发安全性事件。
核心结论
- 给药5年后,etranacogene dezaparvovec在B型血友病成人中有效且安全性良好。
- 受试者可参加扩展研究(NCT05962398)再随访10年。
研究设计与样本
- 2b期、开放标签、单剂量、单臂、多中心试验(NCT03489291)。
- 3例重型或中重型B型血友病(FIX≤2%)且AAV5中和抗体阳性的成年受试者。
- 单次静脉给药etranacogene dezaparvovec 2×10^13基因组拷贝/kg。
主要发现
- 6周时FIX活性≥5 IU/dL的主要终点达到,均值30.6 IU/dL。
- FIX活性均值第1年升至40.8 IU/dL(范围31.3-50.2),第5年维持45.7 IU/dL(范围39.0-51.2)。
- 0至5年累积随访期年均出血率(全部出血)为0.14。
- 2例受试者治疗后5年无出血。
- 按方案,1例受试者治疗后因择期手术、2次出血事件及2次原因未报告的单次自行输注接受按需FIX替代治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Etranacogene dezaparvovec (CSL222, formerly AMT-061) is a recombinant adeno-associated virus serotype 5 (AAV5) vector containing the highly active factor IX (FIX) Padua variant controlled by a liver-specific promoter. This phase 2b, open-label, single-dose, single-arm, multicenter trial evaluated the efficacy and safety of etranacogene dezaparvovec. Three adult participants with severe or moderately severe hemophilia B (FIX ≤2%) and AAV5-neutralizing antibodies received a single IV dose (2 × 1013 genome copies per kg) of etranacogene dezaparvovec. The primary end point of FIX activity ≥5 IU/dL at 6 weeks was met (mean, 30.6 IU/dL). Secondary end points included bleed frequency, FIX concentrate use, and adverse events. Here, we report the end-of-study 5-year outcomes. After administration, mean (range) FIX activity increased to 40.8 IU/dL (31.3-50.2) at year 1 and was maintained at 45.7 IU/dL (39.0-51.2) at year 5. Mean annualized bleeding rate (all bleeds) was 0.14 for the cumulative follow-up period years 0 to 5. Two participants had 5 bleed-free years after treatment. Per protocol, 1 participant received episodic FIX replacement therapy after treatment for elective surgeries, 2 bleeding episodes, and 2 single self-administered infusions for unreported reasons. All participants discontinued and remained free of FIX prophylaxis. During the 5-year study period, there were no clinically significant elevations in liver enzymes, requirement for steroids, FIX inhibitor development, thrombotic complications, or late-emergent safety events in any participant. Five years after administration, etranacogene dezaparvovec was effective in adults with hemophilia B with a favorable safety profile. Participants are eligible to participate in an extension study (ClinicalTrials.gov identifier: NCT05962398) for 10-year additional follow-up. This trial was registered at www.clinicaltrials.gov as #NCT03489291.
引用
- von Drygalski A, Gomez E, Giermasz A, et al. Completion of phase 2b trial of etranacogene dezaparvovec gene therapy in patients with hemophilia B over 5 years. Blood Adv. 2025. PMID: 40188458. doi:10.1182/bloodadvances.2024015291
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。